Young Dublin software firm Automsoft has clinched a multi-million dollar deal with leading international biotechnology player Genzyme to rollout advanced pharmaceutical database technology across the company’s international therapeutic manufacturing locations.
Genzyme will be deploying Automsoft’s Rapid-Pharma database software across its primary therapeutic manufacturing sites where the software will be responsible for all data capture as well as process and plant functions necessary for reporting and analysing activities and trends.
Genzyme is a global biotech company that focuses on making a positive impact on the lives of people with serious diseases. It employs more than 5,000 people in 80 countries.
The Rapid-Pharma software is also being deployed to bring the facilities into compliance with the Federal Drug Administration’s (FDA) 21 CFR Part II ruling.
Phillip Maderia, associate director, Automation Engineering for Genzyme said: “Genzyme selected Automsoft because of its overall competence in providing real-time visibility of the production environment. The Rapid-Pharma data management system meets our requirements for Part 11 compliance, unparalleled ease of use and delivers functionality that allows us to control and manage our production environment.”
Dublin-based Automsoft was established in 1997 and has offices and operations in the US and the UK. The company develops vertically-focused database applications that allow manufacturers in various industries, including the pharmaceutical and oil and gas sectors, optimise production processes by collecting, storing, analysing and reporting on production data to give a reliable picture of the manufacturing process and meet regulatory requirements.
By John Kennedy
